Presentation is loading. Please wait.

Presentation is loading. Please wait.

Antiproliferative effects of JQ-EZ-05 on VHL−/− ccRCC are on-target

Published byMorgan Cobb Modified over 5 years ago

Similar presentations

Presentation on theme: "Antiproliferative effects of JQ-EZ-05 on VHL−/− ccRCC are on-target"— Presentation transcript:

1 Fig. 5. Antiproliferative effects of JQ-EZ-05 on VHL−/− ccRCC are on-target.
Antiproliferative effects of JQ-EZ-05 on VHL−/− ccRCC are on-target. (A) Sequence alignment of EZH1 and EZH2 catalytic SET domains. (B and C) Immunoblots (B) and crystal violet staining (C) of 786-O cells infected to exogenously produce WT or ΔPSET EZH1 and treated with the indicated amounts of JQ-EZ-05 for 3 and 7 days, respectively. (D and E) Photomicrographs (D) and immunoblots (E) of 786-O cells infected with a lentivirus encoding GFP, WT EZH1, or randomly mutagenized EZH1 (XL-Red) and treated with the indicated concentrations of JQ-EZ-05 for 3 days (E) or with either 4 μM JQ-EZ-05 or DMSO for 21 days (D). (F) Crystal violet staining of UMRC-2 cells infected to exogenously produce the indicated EZH1 variants and treated with the indicated concentrations of JQ-EZ-05 for 10 days. (G) Structural model of JQ-EZ-05 bound to WT EZH1. (H) Immunoblots of UMRC-2 cells expressing EZH1 variants as in (F) treated with the indicated concentrations of JQ-EZ-05 for 3 days. Abhishek A. Chakraborty et al., Sci Transl Med 2017;9:eaal5272 Published by AAAS

Download ppt "Antiproliferative effects of JQ-EZ-05 on VHL−/− ccRCC are on-target"

Similar presentations

Fig. 1. Generation of ERY974. Generation of ERY974. (A) Schematic illustration of ERY974 structure and the introduced mutations. The two Fab arms share.

Fig. 1. Generation of ERY974. Generation of ERY974. (A) Schematic illustration of ERY974 structure and the introduced mutations. The two Fab arms share.
Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.

Fig. 6. AZD6738 induces DNA damage and apoptosis and exhibits antitumor efficacy in xenograft models of high-risk medulloblastoma and neuroblastoma. AZD6738.
Differentiation of AZD4785 from MAPK pathway inhibitors in vitro

Differentiation of AZD4785 from MAPK pathway inhibitors in vitro
Fig. 6. dAST directly from clinical samples using dPCR and dLAMP for quantification. dAST directly from clinical samples using dPCR and dLAMP for quantification.

Fig. 6. dAST directly from clinical samples using dPCR and dLAMP for quantification. dAST directly from clinical samples using dPCR and dLAMP for quantification.
Fig. 5. Blocking LTB4 during initial lymphangiogenesis period abrogates the therapeutic benefit of LTB4 antagonism. Blocking LTB4 during initial lymphangiogenesis.

Fig. 5. Blocking LTB4 during initial lymphangiogenesis period abrogates the therapeutic benefit of LTB4 antagonism. Blocking LTB4 during initial lymphangiogenesis.
Fig. 3. Cytokines trigger proliferation and block differentiation of perivascular adipocytes. Cytokines trigger proliferation and block differentiation.

Fig. 3. Cytokines trigger proliferation and block differentiation of perivascular adipocytes. Cytokines trigger proliferation and block differentiation.
Fig. 5. Circulating PPi concentration does not correlate with severity of calcification phenotype in mice. Circulating PPi concentration does not correlate.

Fig. 5. Circulating PPi concentration does not correlate with severity of calcification phenotype in mice. Circulating PPi concentration does not correlate.
Fig. 3 Urinary LAM concentration predicted pulmonary TB and correlated to mycobacterial burden and weight loss. Urinary LAM concentration predicted pulmonary.

Fig. 3 Urinary LAM concentration predicted pulmonary TB and correlated to mycobacterial burden and weight loss. Urinary LAM concentration predicted pulmonary.
Fig. 4. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin expression. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin.

Fig. 4. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin expression. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin.
BET inhibition and depletion repress the expression of BRCA1 and RAD51

BET inhibition and depletion repress the expression of BRCA1 and RAD51
Fig. 7. Role of PDE5 up-regulation in lung cancer–associated PH.

Fig. 7. Role of PDE5 up-regulation in lung cancer–associated PH.
Fig. 3. Antimicrobial activity is detected in diverse strains of CoNS and not predictable at the species level. Antimicrobial activity is detected in diverse.

Fig. 3. Antimicrobial activity is detected in diverse strains of CoNS and not predictable at the species level. Antimicrobial activity is detected in diverse.
Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.

Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.
Strategy for CRISPR/Cas9-mediated genome editing in ΔEx50 mice

Strategy for CRISPR/Cas9-mediated genome editing in ΔEx50 mice
Fig. 2. In vitro profiling of tEV markers on cell line–derived EVs.

Fig. 2. In vitro profiling of tEV markers on cell line–derived EVs.
Fig. 4. Biomechanical properties of treated tibiae.

Fig. 4. Biomechanical properties of treated tibiae.
Fig. 4. Functional annotation of VUS in EGFR.

Fig. 4. Functional annotation of VUS in EGFR.
Fig. 5. Prophylactic treatment with GS-5734 reduces SARS-CoV disease.

Fig. 5. Prophylactic treatment with GS-5734 reduces SARS-CoV disease.
Fig. 1. Schematic representation of the MANO method.

Fig. 1. Schematic representation of the MANO method.
JQ1 directly represses the promoter activities of BRCA1 and RAD51

JQ1 directly represses the promoter activities of BRCA1 and RAD51

Similar presentations

Ads by Google